Jazz Pharmaceuticals: the cheap re-rating is spent, and the stock now banks on Ziihera execution

A year ago, Jazz Pharmaceuticals was the kind of stock value investors argued about: a profitable specialty pharma priced for bad news because its dominant sleep medicine, the narcolepsy drug Xywav, was losing the patent protection that had made it a fortress. The market assumed generics would grind the franchise down.

The market was wrong, and the proof is in the price. Jazz is up about 95% over the past twelve months, sits near its 52-week high around $246, and in May UBS upgraded Jazz to Buy, raising its price target from $188 to $307. The question for anyone looking at the stock today is not whether the company improved. It did, decisively. The question is how much of that improvement is already in the price, because the easy part of this trade — buying a hated, cheap stock before the re-rating — is over.

The oxybate scare receded instead of landing

Start with the business the market was wrong about. Xywav, the low-sodium follow-on to Xyrem for narcolepsy and idiopathic hypersomnia, is still growing despite generic competition. In the second quarter Xywav net sales rose 13% year over year to $471 million, with 525 net new patients, ending the quarter at roughly 17,125 active patients. Older Xyrem, the franchise's aging original, is shrinking — down to $30.5 million a quarter — but the larger Xywav base is compounding, and management expects the sleep franchise to keep growing double digits for the full year.

The sleep business matters because it is the cash engine that funds everything else, and it proved more durable than the multiple once assumed. Jazz's free cash flow came to about $1.4 billion over the trailing year at roughly a 30% margin, and the balance sheet is comfortable: $2.2 billion in cash against $4.4 billion in long-term debt after retiring $1 billion of notes in June. Cheap, durable cash flow is what let the market re-rate the story as something other than a liquidation.

Oncology turned into a second engine — and Ziihera is the new bet

What changed the perception from "one-drug company in decline" to "growth pharma" is that oncology stopped being a rounding error. Total oncology revenue grew 32% in Q2. Zepzelca jumped 42% to $106 million on its first-line maintenance use in small-cell lung cancer, and Ziihera — the company's HER2-targeting antibody for biliary tract cancer — is its newest product.

The big catalyst arrived in August. The FDA approved Ziihera on Aug. 25 in first-line HER2-positive gastroesophageal adenocarcinoma, a far larger market than its current biliary indication, on the back of an overall-survival benefit Jazz reported days later. Record second-quarter revenue of $1.21 billion, up 16%, led Jazz to raise its full-year 2026 guidance to $4.60–$4.75 billion from $4.25–$4.50 billion.

This is the crux of the bull case. UBS models Ziihera reaching roughly $3.1 billion in peak sales, and it frames the whole story as faster, more durable growth: a 10% revenue CAGR and 11% EPS CAGR through 2030, versus roughly 7% and 6% for consensus. That estimate is why the bank feels comfortable with the higher number.

The valuation has already moved with the outlook

But here is where an honest read has to separate the company from the stock. The cheap multiple that made Jazz a bargain a year ago has been largely repriced. The stock trades at roughly 17 times trailing earnings and about 14 times EV/EBITDA. That is still below some faster-growing specialty-pharma peers — Neurocrine sits near 22 times earnings — but Jazz is no longer a cheap-reset story; it is a growth story priced like many growth stories, with the upside depending on execution rather than a valuation catch-up.

That makes the strongest bear facts worth naming. Ziihera's current biliary sales are only about $15 million a quarter — the $3.1 billion peak is a projection, not revenue. GAAP profitability remains thin, dragged down by charges like the $0.94 per-share in-process R&D in Q2, and reported earnings are negative on a static basis after years of deal-related amortization. Gross margin is under modest pressure as royalty-bearing oncology products like Zepzelca and Modeyso take a bigger share of the mix. And the sleep franchise that funds all of this still faces an uncertain generic picture a few years out.

So the trade has inverted from what it was. The re-rating off the lows — the part where risk was real but the valuation had already discounted it — is done. What remains is a bet that Ziihera launches into its much larger gastroesophageal market at a credible ramp, that Zepzelca's first-line momentum holds, and that Xywav keeps compounding against generics. Those are the proof points of the next two to four quarters, and they now have to do heavier lifting than the valuation once did.

None of that makes Jazz a bad company. It has real growth, real cash flow, and a newly approved product with survival data behind it. But the gap between the stock at $246 and UBS's $337 largely assumes that execution goes as planned. The market has already paid up for most of the good news; the remaining upside is owned by Ziihera and oncology actually delivering it.